

Pharmacogenomics (Hinxton, UK)

Session 1 TRANSLATION INTO CLINICAL PRACTICE—WARFARIN AS A PARADIGM WEDNESDAY 10/17/2007, 3:00 PM

R. Weinshilboum / A. Coffey

#	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
1	Duff	Translation of genetic knowledge into clinical practice—The expectations and realities of personalized medicines	25
2	Johnson	The International Warfarin Pharmacogenetics Consortium	25
3	Rieder	A whole genome scan for polymorphisms influencing warfarin dosing	25
4	Becquemont	Pharmacogenetics of vitamin K antagonists	25
5	Oldenburg	VKORC1 mutations and resistance to anticoagulants	25
6	Lesko	Warfarin pharmacogenomics—Translation into clinical practice	25

Session 2 CANCER PHARMACOGENOMICS THURSDAY 10/18/2007, 9:00 AM

C.R. Wolf / A. Futreal

#	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
7	Futreal	Somatic cancer genetics—Insights and implications from large-scale resequencing efforts	25
8	Delmar	Pharmacogenetics of erlotinib in advanced non-small cell lung cancer (NSCLC)—Results from the merit study	25
9	Brauch	Gene variants in tamoxifen metabolizing enzymes CYP2D6 and CYP2C19 predict breast cancer endocrine therapy outcome	25
10	Caronia	DNA-repair polymorphisms predict cisplatin response in osteosarcoma patients treated with platinum chemotherapy	25
11	Ross	Pharmacogenetics of severe ADRs in children—Identification of novel genomic markers of cisplatin-induced deafness in children	25
12	Roberts	Promoter insertion in an inflammatory bowel disease patient exhibiting ultra-high thiopurine S-methyltransferase activity	25

Session 3 HUMAN GENOME VARIATION THURSDAY 10/18/2007, 2:00 PM

V. Cheung / M. Hurles

#	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
13	van der Spoel	Pharmacogenetics in mice—Differences between mouse strains in sensitivity to <i>N</i> -alkylated imino sugars	25
14	Wang	Pharmacogenetics of cytidine analogues—Application of a cell-based model system	25
15	Potter	Association of RF and anti-CCP positivity, but not carriage of shared epitope or <i>PTPN22</i> susceptibility variants, with anti-TNF response in RA	25
16	Hurles	Structural variation in the human genome	25

Session 4 POSTER SESSION I

THURSDAY 10/18/2007, 5:30 PM

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
18	Molokhia	The common ABCB1 variants C1236T, G2677T, C3435T, and their haplotypes are associated with increased digoxin serum concentration	
19	Andrews	The potential of pharmacogenetics for optimizing the use of methotrexate in psoriasis patients	
20	Alfirevic	Association of <i>ACE</i> , <i>AGT</i> and <i>AGTR1</i> genes in a randomized controlled trial using lisinopril for one year in renal transplant recipients with proteinuria and chronic allograft nephropathy	
21	Alfirevic	Carbamazepine alters expression of lymphotoxin alpha from B-cells in a genotype-dependent manner	
22	Anderson	Polymorphisms in the β_2 -adrenergic receptor (<i>ADRB2</i>) do not modulate clinical response to the long-acting β agonist salmeterol in a large prospective study	
23	Port	Improvement in heart failure therapy by genetic targeting	
24	Bromley	Recommendations from the pharmacogenetics working group on the design and analyses of pharmacogenetic studies	
25	Ross	Canadian National Active Surveillance Network for Adverse Drug Reactions—Genotypic adjustment of therapeutics in children (GATC)	
26	Cecchin	UGT1A7*3 polymorphism as a predictive marker of severe therapy-related toxicity in advanced colorectal cancer patients treated with FOLFIRI regimen (5-FU/LV/irinotecan)	
27	Chiang	Meta-analysis of gene expression data on cancer drugs from an international repository	
28	Cotsapas	Identifying the genetic components of drug response in mice	
29	Dong	Circadian rhythm genes in alcohol dependence	
30	Newman	Exploring patients' and healthcare professionals' preferences for pharmacogenetic testing services	
31	Feidt	RNA-interference approaches to study functions of NADPH:cytochrome P450 oxidoreductase	
32	Fernandes	Multiple Sclerosis Brazilian patients present different metalloproteinase (MMP)-9 genotypes and MMP-9 activity compared to healthy volunteers	
33	Fu	New technologies for sensitive and accurate detection of rare sequence variants	
34	Girard	New UGT1A proteins with regulatory properties	
35	Kennedy	Functional effects of polymorphisms in the promoter of <i>HES6</i> , a candidate gene for antidepressant response	
36	Gomes	Variability of NADPH:Cytochrome P450 oxidoreductase in human liver—Role of genetic polymorphisms and nongenetic factors	
37	Gunes	Influence of genetic polymorphisms and environmental factors on <i>CYP1A2</i> phenotype	

38	Jang	Influence of the β adrenergic receptor (AR) genetic polymorphisms on the pharmacodynamics of sevoflurane
39	Ji	Association between mirtazapine-induced weight gain and polymorphisms of β 1, β -2 and β -3 adrenergic receptor gene in Korean patients with major depressive disorder
40	Kang	Serotonin 1A receptor gene polymorphism and mirtazapine responses in Koreans with major depression
41	Kim	Differential gene expression associated with sensitivity of CDK-602 (Belotecan) on 14 human gastric cancer cell lines
42	Klein	PharmGKB—The pharmacogenetics and pharmacogenomics knowledge base
43	Reck	Pharmacogenetics of drug induced liver injury—Potential mechanisms of aplaviroc hepatotoxicity
44	Lee	CYP2B6 single nucleotide polymorphisms (SNPs) influence on tolerance, outcome and cyclophosphamide pharmacokinetics (PK) in breast cancer patients receiving adjuvant CMF chemotherapy
45	Lee	MRP1 polymorphism is associated with citalopram response in depressive disorder
46	Lee	Extensive evaluation of CYP2D6 genetic polymorphisms and the influence of its genotype on dextromethorphan metabolism in a Korean population
47	Lee	A promoter polymorphism in histone deacetylase 1 (<i>HDAC1</i>) is significantly associated with oral prednisolone responsiveness in asthmatics

Session 5 PHARMACOGENETICS IN NEUROPSYCHIATRIC DISEASE

FRIDAY 10/19/2007, 9:00 AM

M. Eichelbaum / D. Goldstein

#	Iname	Title	Talk Length
48	Propping	Pharmacogenetics and schizophrenia	25
49	Kukreti	Pharmacogenetics and critical candidate genes involved in drug response for schizophrenia	25
	Kennedy	Gene expression changes cause by paroxetine—New clues for antidepressant action?	25
50	Goldstein	Neuropsychiatric genetics and pharmacogenetics	25
51	Jose	Characterization of the phenotype-genotype relationships for GABA transaminase	25
52	Madadi	Pharmacogenetics of codeine toxicity during breastfeeding	25

Session 6 POSTER SESSION II

FRIDAY 10/19/2007, 5:30 PM

#	Iname	Title	Talk Length
53	Kennedy	Sepiapterin reductase (SPR)—A novel candidate gene for antidepressant response?	
54	Molokhia	Statin induced myopathy—Time trend analysis and comparison of risk associated with statin class using case-crossover approach with 93,831 patients from primary care data 1991-2006	
55	Newman	CYP2D6*4 is associated with earlier breast cancer recurrence in individuals with familial breast cancer treated with tamoxifen	
56	O'Brien	First report of warfarin dose requirements in patients possessing the CYP2Cp*12 allele	

57	Oliveira	The role of nine pharmacogenetic polymorphisms in treatment and outcome of childhood acute lymphoblastic leukemia
58	Palei	Altered plasma levels of matrix metalloproteinases (MMP-2/-9) and tissue inhibitor of metalloproteinases (TIMP-1/-2) in pre-eclamptic pregnancy
59	Wool	INDEL based genotyping approach discovers a novel potential predisposition locus for type II diabetes
60	Rane	Genetics of androgen disposition—Implications for doping tests
61	Rotger	Functional polymorphisms in alternative metabolic pathways (<i>CYP3A</i> and <i>CYP2A6</i>) lead to extreme efavirenz exposure in individuals with limited <i>CYP2B6</i> function
62	Rothe	Calcium-sensing receptor gene polymorphism Arg ⁹⁹⁰ Gly influences the response to calcimimetic agents both in end-stage kidney disease patients with secondary hyperparathyroidism and in cell culture
63	Saab	The geographic distribution of the ACE II genotype—A novel finding
64	Sandrim	eNOS polymorphism frequencies are significantly different among healthy pregnant, gestational hypertension and preeclampsia, besides modify nitrite levels and blood pressure values in these groups
65	Schwab	Determination of TPMT polymorphisms in different ethnic groups by MALDI-TOF MS
66	Scordo	No effect of <i>CYP3A4/CYP3A5</i> polymorphisms on donepezil kinetics and clinical outcome in patients with Alzheimer's disease
67	Semsei	Influence of the GGH-401C>T polymorphism on methotrexate kinetics and toxicity in children with osteosarcoma
68	Shah	Molecular modeling and pharmacogenetics of cytochrome 2D6
69	Shim	Characterization of metformin transport by most prevalent polymorphisms of hOCTs in a Korean population
70	Shin	Enhancement of mutated α -galactosidase A activity by pharmacological chaperones
71	Andrews	Interim TPMT metabolite measurements in patients undergoing azathioprine therapy
72	Sisay-Joof	Effects of genetic variations in a cytochrome P450 enzyme (<i>CYP2C19</i>) on pharmacokinetics and clinical effectiveness of antimalarial drugs
73	Smith	Seeking pharmacogenetics loci which explain non-TPMT related side effects in patients taking azathioprine for inflammatory bowel disease
74	Sugden	Gene expression analyses of a mouse fibroblast cell line after antidepressant treatment
75	Sundseth	Genome-wide SNPS data analysis—Comparison of statistical methods for marker discovery and replication
76	van Schaik	<i>CYP3A5</i> genotype is not associated with acute rejection in tacrolimus/MMF treated kidney transplant patients
77	Veenstra	The cost-effectiveness landscape of genetic testing with warfarin therapy
78	Veenstra	Pharmacokinetic-pharmacodynamic-pharmacoeconomic (P^3) modeling to inform pharmacogenomic trial design and risk management
79	Wadelius	Warfarin dose associated with candidate genes

- 80 Rousseau Influence of *CYP3A* and *ABCB1* donor genotype on graft loss in a retrospective cohort of renal transplant patients receiving cyclosporine A
- 81 Woo Comparison of the difference in the prevalence of *CYP2C19* poor metabolizer between Korean and four populations using international HapMap database

Session 7 EPIDEMIOLOGICAL APPROACHES IN PHARMACOGENOMICS

SATURDAY 10/20/2007, 9:00 AM

A. Morris / P. McKeigue

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
82	Morris	Record linkage in Scotland—Options and opportunities for post-genomic pharmacogenetics research	25
83	Bromley	Risk modeling strategies for pharmacogenetic studies	25
84	Coller	Impact of <i>ABCB1</i> genetic variability on renal transplantation	25
	McKeigue	Genetic studies of type B adverse reactions—Problems of design and analysis	25
85	Chen	A search for genetic factors underlying bleeding complication in warfarin treatment	25
86	Hughes	Prospective validation of HLA-B*5701 screening to reduce the incidence of hypersensitivity to Abacavir in a controlled clinical study	25

Session 8 ADVERSE DRUG REACTIONS

SATURDAY 10/20/2007, 2:00 PM

M. Pirmohamed / J.S. Leeder

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
87	Veenstra	Economic consequences of ADRs and potential impact of pharmacogenomics	25
88	Holden	The Serious Adverse Event Consortium, Ltd.—Formation of an international effort to understand the genetic basis of drug related serious adverse events	25
89	Bowman	Pharmacogenetics of drug-induced blistering skin reactions	25
90	Inui	Pharmacogenomics on tacrolimus therapy in liver transplant patients	25
91	Park	Phenotype versus genotype in causation of adverse drug reactions	25